Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.52 |
| ▸ | AR | P10275 | 4/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517244 | 0.99 | PGR (0.71) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5515576 | 0.98 | PGR (0.72) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5512561 | 0.87 | PGR (0.72) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5522445 | 0.86 | PGR (0.71) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5512888 | 0.85 | PGR (0.72) | PGRNR3C2ARNR3C1 | |
| SCHEMBL61743 | 0.84 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL4185522 | 0.83 | PGR (0.98) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5518269 | 0.81 | PGR (0.74) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5508205 | 0.81 | PGR (1.00) | PGRNR3C2ARNR3C1 | |
| SCHEMBL5515556 | 0.80 | PGR (0.72) | PGRNR3C2ARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268149-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-7192956-B2 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1515725-A4 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1515725-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH | 2004-01-22 | — | — | US | disclosed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | PGR 46/4885NR3C2 75/4885AR 118/4885 |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | NR5A1, MC1R, CYP17A1 | PGR 7/4885NR3C2 27/4885AR 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.